All News
Can tender and swollen joint counts work in a telemedicine world?
In a world where telemedicine and virtual care are not going away, is there value in patients assessing their own tender and swollen joints?
Read Article
Minimal disease activity achievement in PsA achieved by 22.8% in 6 mo of b/ts DMARD
MDA achievers were:
➡️Younger
➡️🔽 Disease duration;
➡️ Male
➡️Non-obese
➡️bDMARD-naïve at baseline
➡️🔼 probability achieving MDA components➕MCID PROMs at 6 mo
Abst# 1344 #ACR21 @Rheumnow
swethaann23 swethaann23 ( View Tweet)
Effect of BMI on PRO treatment response in PsA. Increasing BMI associated with lower response. More pronounced in TNFi than IL-17 or JAKi. Abstr#1327 #ACR21 @RheumNow https://t.co/qhgVlW72uM
Richard Conway RichardPAConway ( View Tweet)
In this study,
⭕AS pts w/>=2 #comorbidities were associated w/ poorer outcome measures after 2 yrs of ffup vs. pts w/ no comorbids
⭕Pts w/ >=2 comorbids were likely to dc 1st anti-TNF
Address comorbidities, ⬆ chances of better outcomes & QoL
@RheumNow #ACR21 abs1309 https://t.co/sTnjaC1a1l
sheila RHEUMarampa ( View Tweet)
#ACR21 Abs#1225: B/L Extracell Matrix Biomarkers predict ABA response in MTX-naive, +ACPA early RA
⭐️ECM biomarkers predict SDAI remission or DAS28 w ABA+MTX vs PBO+MTX.
⭐️⬆️CTX1 biomarker predicts efficacy endpts for ABA+MTX
https://t.co/7wHQefb5D4 @Rheumnow
Links:
Eric Dein ericdeinmd ( View Tweet)
Wk 12 disease activity predicts wk 24/26 remission/low disease activity with #upadacitinib 15mg in MTX-naïve or inadequate responders to MTX and/or TNFi pts.
≥50% improvement in SJC/TJC at Wk 12 was assoc with wk 24/26 remission/low disease activity.
Abs#1237 #ACR21 @RheumNow https://t.co/PAaCe5MAcu
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR21 - Starting soon - The Gift of Gab! with @BayviewMedicine @jhrheumatology Jason Liebowitz moderating Communication for the Physician with @Wharton Janet Zeide. Learn about the RHEUM acronym for speaking! @Rheumnow https://t.co/wcgFUBcZeX
Eric Dein ericdeinmd ( View Tweet)
EULAR update on vaccines. HZ vaccine safe with csDMARDs and TNFα blockers. Reduced cell immune response after 1 year. Assess Varicella Abs if exposure unknown. Non-live recombinant subunit adjuvant zoster vaccine may be a game changer @RheumNow #ACR21 8M101 https://t.co/PTLqYGRIGf
Dr. Antoni Chan synovialjoints ( View Tweet)
Innovative!
Self-home fetal heart rate monitoring by the mother is feasible, accurate, effective for those with +anti-Ro/SSA Ab.
The study is still recruiting https://t.co/9BFihsgW5A Abst#1464 #ACR21 @rheumnow
https://t.co/ggmOpSGdZk
Links:
TheDaoIndex KDAO2011 ( View Tweet)
RheumNow’s expanded coverage of #ACR21 is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Abs#1036: illness-related uncertainty significantly correlates with #depression, #anxiety, and sickness impact in patients with autoimmune #rheumaticdiseases.
Particularly strong associations with #AAV and #SSc.
#MentalHealth #ACR21 @RheumNow
https://t.co/SiV9fst3Bh https://t.co/w8VRQHdAJC
Mrinalini Dey DrMiniDey ( View Tweet)
⚡️A new biomarker of structural progression in RA? Plasma levels of CXCL13 ⬆️ @ baseline vs. ctrl and ⬇️ (p< 0.0001) after 1 yr treatment in a eRA cohort. Levels above 85pg/ml ⬆️ x5 risk of > severe radiographic status at 11yrs. @RheumNow #ACR21 #Abst1204 https://t.co/LnkayR1YrY https://t.co/W0xsgGuUDW
Aurelie Najm AurelieRheumo ( View Tweet)
#ACR21 Abst#1204. CXCL13 predicts long-term radiographic status in early RA
▶️ early RA has ⬆️ CXCL13, and ⬇️ w treatment
⭐️CXCL13 was best predictor of long-term radiographic destruction - better than DAS28CRP and CRP
@Rheumnow https://t.co/ydYRbKMBZ2 https://t.co/qinEFb86Az
Links:
Eric Dein ericdeinmd ( View Tweet)
Increased risk of vertebral fractures in PsA pts
OR 2.09 from meta-analysis and systematic review
Abs#1304
#ACR21
@RheumNow
https://t.co/0IazVBGHsF https://t.co/YrPMh1TZ6U
Robert B Chao, MD doctorRBC ( View Tweet)
#ACR21 Abst#1229: Does BMI influence efficacy of SC (fixed dose) vs IV (body-wt adjusted) ABA in RA?
⭐️No difference between SC and IV ABA by BMI
⭐️BMI impacts response to ABA as >2nd line therapy and retention, but no difference bw dosing
https://t.co/LqfZvLhBzU @Rheumnow
Links:
Eric Dein ericdeinmd ( View Tweet)
Is #calprotectin the new ESR/CRP?
👉🏼SLR finds calprotectin correlates w/ ultrasound synovitis in RA
👉🏼In some studies, it was a better biomarker than ESR/CRP
👉🏼It can distinguish ultrasound remission from subclinical synovitis
Abs#1207 #ACR21 @RheumNow
https://t.co/ADkRBq5KoG
Mrinalini Dey DrMiniDey ( View Tweet)
CATCH cohort: PT CDAI and MD CDAI correlate good to strongly at 3 and 6mo in patients with no non articular pain or w/regional pain but 🚨 NOT in pts w/ widespread pain! We should find alternative remote DA measures for this pop. #ACR21 @RheumNow #Abst1202 https://t.co/LsCtsfXsN1 https://t.co/gjeGxBA0HB
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
My video summary on this important piece of work by @Sineadm15 is now available to watch on @RheumNow:
https://t.co/Gh64D4PADw
#ACR21 #MentalHealth #Depression #AxSpA https://t.co/EcH4VDs2Xi
Links:
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR21 Abs#1196: Morning stiffness (MS) in pre-RA arthralgia associates w inflammation
⭐️Arthralgia pts: 14% ACPA+, 34% w MS
MS correlates w ⬆️subclinical synovitis/tenosynovitis on MRI and higher CRP. Duration of morning stiffness correlates
https://t.co/DUhgjbjQIr
@Rheumnow https://t.co/dHl7LuY3ZA
Links:
Eric Dein ericdeinmd ( View Tweet)
We need to be better at identifying and managing #depression in patients with #axspa.
In a group of 70 pts, many had high HADs-D & PHQ-9, with worse disease activity & #QoL compared to those with normal scores.
Abs#1305 #ACR21 @RheumNow
https://t.co/lNoo0HfMcC https://t.co/n7Vyl9L5FR
Mrinalini Dey DrMiniDey ( View Tweet)
